Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer. Ros J, Elez E. Eur J Cancer 2022;172:326-328.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ros J, Elez E. Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer. Eur J Cancer 2022;172:326-328.
PMID: 35820242